"Our platform can be easily adapted for point-of-care diagnostics to detect a broad range of viral pathogens in resource-limited clinical settings at the far corners of the world, in defense and homeland security applications as well as in civilian settings such as airports," said Altug.
Connor noted an additional, significant advantage of the new technology. "It will be relatively easy to develop a diagnostic device that simultaneously tests for several different viruses," he observed. "This could be extremely helpful in providing the proper diagnosis."
The new biosensor is the first to detect intact viruses by exploiting plasmonic nanohole arrays, or arrays of apertures with diameters of about 200 to 350 nanometers on metallic films that transmit light more strongly at certain wavelengths. When a live virus in a sample solution, such as blood or serum, binds to the sensor surface, the refractive index in the close vicinity of the sensor changes, causing a detectable shift in the resonance frequency of the light transmitted through the nanoholes. The magnitude of that shift reveals the presence and concentration of the virus in the solution.
"Unlike PCR and ELISA approaches, our method does not require enzymatic amplification of a signal or fluorescent tagging of a product, so samples can be read immediately following pathogen binding," said Altug. Ahmet Yanik, Altug's research associate who conducted the experiments, added, "Our platform can detect not only the presence of the intact viruses in the analyzed samples, but also indicate the intensity of the infection process."
The researchers are now working on a hi
|Contact: Mike Seele|
Boston University College of Engineering